NCT01919385

Brief Summary

This study will be conducted in a Clinical Research Center (CRC) setting and recruiting type 1 diabetes that are currently using an insulin pump.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jul 2013

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 28, 2013

Completed
3 days until next milestone

Study Start

First participant enrolled

July 1, 2013

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 9, 2013

Completed
23 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
Last Updated

September 19, 2013

Status Verified

September 1, 2013

Enrollment Period

2 months

First QC Date

June 28, 2013

Last Update Submit

September 17, 2013

Conditions

Keywords

Type 1 diabetesInsulin Pump

Outcome Measures

Primary Outcomes (1)

  • Evaluate the performance of the System while the subject is under close medical supervision in the Clinical Research Center (CRC) setting

    Evaluating the ability of the system to predict a fall or rise in glucose values below or above a low glucose threshold, and take the corresponding appropriate action of reducing or suspending insulin delivery in order to keep the subject's glucose above this threshold, or resuming insulin delivery at the current basal rate upon the increase of glucose above this threshold. Ability of the system to issue timely and accurate warnings.

    1 week after subject is enrolled in the study

Secondary Outcomes (1)

  • Capturing the number of Adverse Events as a measure of assessing subject safety

    1 week after subject is enrolled in the study

Study Arms (1)

type 1 diabetes

EXPERIMENTAL

Predictive Low Glucose Minimizer (PLGM) System

Device: Predictive Low Glucose Minimizer

Interventions

This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.

Also known as: type 1 diabetes
type 1 diabetes

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 21-65 years
  • Type 1 diabetes mellitus for at least one year
  • Currently using an insulin infusion pump for at least the past 6 months

You may not qualify if:

  • Pregnancy
  • History of Diabetic Ketoacidosis (DKA) in the past six months
  • History of severe hypoglycemia (Seizure, unconsciousness) in the past 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsum Diabetes Reserach Inst.

Santa Barbara, California, 93105, United States

Location

Related Publications (1)

  • Finan DA, Dassau E, Breton MD, Patek SD, McCann TW Jr, Kovatchev BP, Doyle FJ 3rd, Levy BL, Venugopalan R. Sensitivity of the Predictive Hypoglycemia Minimizer System to the Algorithm Aggressiveness Factor. J Diabetes Sci Technol. 2015 Jun 30;10(1):104-10. doi: 10.1177/1932296815593292.

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Howard Zisser, MD

    Samsum Diabetes Reserach Inst.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 28, 2013

First Posted

August 9, 2013

Study Start

July 1, 2013

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

September 19, 2013

Record last verified: 2013-09

Locations